ArticleWorld journal of urology2025
Evaluating the likelihood of pediatric sacral nerve stimulator explantations due to cure or complications: a survival analysis of 13-year institutional cohort.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSacral neuromodulation (SNM) is a treatment option for children with refractory bladder and bowel dysfunction. Prior investigations have shown children may achieve cure of their symptoms following SNM implants and subsequently have their devices explanted. Herein, we present a 13-year experience of pediatric SNM placements and evaluate the likelihood of SNM explantation for any cause, for symptom resolution or complications.
methodsAn institutional retrospective review of children who underwent a 2nd stage SNM placement between November 2012 and January 2025 was performed. Reasons for SNM explantation was categorized as a cure or complication. Competing-risk time-to-event analysis was used.
resultsThere were 129 SNM placements at a median of 10 years old (IQR 8.1-12.7); 88 were females (68.2%) and 41 required SNM revision (31.8%). Median follow-up was 3.5 (IQR 2.0-5.3) years. Subsequently, 46 underwent SNM explantation (35.7%). On survival analysis, median time to explantation (50%) was 6.0 (IQR 4.6-7.3) years. Among explanted, 34 were due to symptom resolution (73.9%) and 13 due to complications (4 infections; 4 pain at site; 3 for MRI requirements; 1 clinically ineffective). On competing risks analysis, 72.5% of the explantations at 6 years were for cure and 27.5% for complications. The 6-year explantation risk was 36.3% for cure and 13.8% for complications. Among 17 children who provided data after device explanation following cure (response rate: 51.5%), 16 (94%) had sustained symptom resolution at a median of 3.8 years (IQR 1.3-5.3) after explantation.
conclusionApproximately quarter of children with SNM placement achieved cure with increasing probability with follow-up time. More than 70% of explantations are due to cure and less than 10% were due to infections. There is high likelihood of sustained symptom resolution following explantation for cure. SNM remains a safe and viable option for children with refractory BBD with potential for cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.